Astellas Pharma US Inc., a U.S. affiliate of Astellas Pharma Inc., has entered into a sponsored research agreement with the University of Massachusetts Medical School (UMass Chan Medical School) to conduct research for an AAV vector-mediated gene therapy for the treatment of Alexander disease.
The CMT Research Foundation has formed a strategic partnership with Revir Therapeutics Inc. to advance small-molecule therapeutics that modulate the expression of the gene that causes Charcot-Marie-Tooth disease type 1A (CMT1A).
Oblique Therapeutics AB has entered into an agreement with the KTH Royal Institute of Technology to utilize KTH’s supercomputer resources for analyzing protein structures.
Italfarmaco SpA and Iktos SA have entered into a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.
Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target.
Alivexis Inc. has entered into a research collaboration agreement with Astellas Pharma Inc. to identify small-molecule compounds for a new drug target selected by Astellas.
Sibylla Biotech SpA and the University of Texas MD Anderson Cancer Center have signed a strategic collaboration agreement to discover and develop novel small molecule folding interfering degraders (FIDs) for the treatment of cancer.
Biosplice Therapeutics Inc. has entered a collaboration with Novo Nordisk A/S to develop first-in-class drug candidates for the treatment of diabetes. Biosplice is developing highly selective and potent dual-specificity tyrosine-regulated kinase (DYRK) inhibitors to stimulate insulin-secreting β-cell proliferation for the treatment of diabetes.
Flagship Pioneering Inc. and Profound Therapeutics Inc., a Flagship-founded company, have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.
Evotec SE has announced scientific progress within its neuroscience collaboration with Bristol Myers Squibb Co., with a target-based program now advancing into late preclinical development. This milestone triggers a research payment of $20 million to Evotec.
RSS
